Kura Oncology reports Phase 1b KOMET-001 data for ziftomenib in R/R AML; 600 mg shows 25% CR/CRh

Kura Oncology, Inc.

Phase 1b at 600 mg (N=12): 25% CR/CRh rate, 33% composite CR (75% MRD-), 42% ORR.
Phase 1a (N=30): 2 DLTs (pneumonitis at 400 mg, differentiation syndrome at 1000 mg); manageable safety.
Differentiation syndrome occurred in 7 Phase 1b patients; severity declined after DS Guidance implementation.
Oral presentation at ASH on Dec 10, 2022, will include preliminary data from 18 additional Phase 1b extension patients.
Ziftomenib is an oral menin-KMT2A inhibitor targeting NPM1m and KMT2Ar relapsed/refractory AML.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.